Quotes

Company Overview

Financial Analysis

Main Composition Key Indicators Financial Statement

Multi-dimentional Analyses

Company Valuation Capital Tracking Short Selling Data

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.

CEO： Simpson, Adam K.

Market： NASDAQ

Hot List

TradeSearchNews

SymbolLatest price%Chg

Moomoo > Quotes > ICVX Icosavax > Detailed Quotes

ICVX Icosavax

7.800-0.410-4.99%

Close 05/19 20:00 ET

High

8.420

Open

8.070

Turnover

864.67K

Low

7.720

Pre Close

8.210

Volume

109.57K

Intraday

Price Forecast

No Data

ICVX Icosavax

News

Comment

News

Announcement

All

Earnings Report

Related Transactions

Changes In Ownership

Major Events

Other